Skip to main navigation Skip to search Skip to main content

Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study

  • Yu-Jia Huo
  • , Shu Cheng
  • , Hong-Mei Yi
  • , Ting Niu
  • , Lei Fan
  • , Guo-Hui Cui
  • , Fu-Ling Zhou
  • , Xian-Min Song
  • , Fei Li
  • , Ou Bai
  • , Xiao-Jing Yan
  • , Jun Shi
  • , Ming-Ci Cai
  • , Yao-Hui Huang
  • , Lei Dong
  • , Jie Xiong
  • , Song Hu
  • , Yu-Ran Qiu
  • , Yan Zhao
  • , Peng-Peng Xu
  • Li Wang, Min Lu, Hong-Mei Jing*, Wei-Li Zhao*
*Corresponding author for this work
  • Shanghai Jiao Tong University
  • Sichuan University
  • Nanjing Medical University
  • Huazhong University of Science & Technology
  • Nanchang University
  • First Hosp Jilin Univ
  • First Hosp China Med Univ
  • Pole Rech Sino Francais Sci Vivant & Genom
  • Peking Univ Third Hosp

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Background Peripheral T-cell lymphoma (PTCL) represents a highly heterogeneous group of non-Hodgkin's lymphomas, often with aggressive biological behaviour. CD30 serves as a pivotal surface antigen in PTCL, however, its biological functions and therapeutic potential warrant further investigation. Methods We analysed 415 de novo patients with PTCL including 314 in the training cohort and 101 in the validation cohort across 11 medical centres in China. Genomic and transcriptomic profiles were examined by DNA-and RNA-sequencing in 355 and 169 patients, respectively. Findings In both cohorts, CD30+ PTCL presented significantly increased frequencies of SETD2, STAT3, and PTPRS mutations. Therefore, three molecular subtypes with distinct biological signatures were identified, including the HMA subtype characterised by dysregulation of histone methylation and acetylation, the JNE subtype by alterations in JAK-STAT, Notch signalling pathway, and EBV infection, and the PCT subtype by mutations in phosphorylation, chromatin remodelling, and T-cell receptor-major histocompatibility complex interaction, with extracellular matrix enrichment. Clinically, the JNE subtype demonstrated inferior progression-free survival (PFS) and overall survival (OS), as compared to the HMA and PCT subtypes. Brentuximab vedotin (BV)-containing treatment was associated with improved PFS and OS in the JNE and PCT subtypes. Furthermore, gene expression profile analysis demonstrated underlying vulnerabilities for the HMA, JNE, and PCT subtypes to epigenome-targeting agents, JAK or PI3K inhibitors, and PD-1 inhibitors, respectively. Interpretation The molecular subtypes of CD30+ PTCL demonstrated prognostic significance and varied sensitivity to BV treatment. Our findings further elucidated molecular regulatory networks of CD30+ PTCL, providing potential co-targeted approaches for genotype-guided precision medicine in PTCL. Copyright (c) 2025 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Original languageEnglish
Article number105693
Number of pages16
JournalEBIOMEDICINE
Volume115
Early online dateApr 2025
DOIs
StatePublished - May 2025

Funding

This study was supported by National Key R&D Program of China, National Natural Science Foundation of China, Clinical Research Plan of Shanghai Hospital Development Centre, Shanghai Clinical Research Centre for Cell Therapy, Shanghai Municipal Health Commission, and China Postdoctoral Science Foundation.

Keywords

  • Peripheral T-cell lymphoma
  • CD30
  • Molecular subtype
  • Microenvironment
  • Targeted therapy
  • Brentuximab vedotin

Indexed by

  • SCIE
  • Scopus

Fingerprint

Dive into the research topics of 'Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study'. Together they form a unique fingerprint.

Cite this